Microchannel Tech Cp (MCTC) 0.0040 $MCTC
BioLight Announces Issuance of U.S. Patent for the Long-Term Controlled-Release Drug-Delivery Insert Platform
PR Newswire - Wed Jul 02, 8:23AM CDT
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT) (OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces the U.S. Patent and Trademark Office has issued patent number 8,765,166 covering the device that is inserted into the eye to treat an ocular condition that contains an active agent of a free acid salt form of a prostaglandin with a low elution rate profile that is contained in the long-term controlled-release insert platform. The patent will be in effect at least until May 2031. This patent covers the technology used in Eye-D®, the company's controlled-release latanoprost insert currently in a Phase 1/2a clinical study in the U.S. for the treatment of glaucoma.
BOLT: 21.99 (+0.01)
BioLight Reports Successful Interim Results from Bladder Cancer Clinical Study
PR Newswire - Tue Jul 01, 4:23PM CDT
BioLight Life Sciences Investments Ltd. (OTC: BLGTY)(TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that Micromedic Technologies (TASE: MCTC), BioLight's cancer diagnostic cluster company, achieved successful interim results in a blinded bladder cancer clinical trial with its CellDetect® technology. As a result, Micromedic will continue the trial with the goal of developing a kit for monitoring the recurrence of bladder cancer. This study is being conducted at seven medical centers and is expected to be completed in the fourth quarter of 2014.
BOLT: 21.99 (+0.01)
First Patient Enrolled in FDA Phase 1/2a Clinical Trial With BioLight's Controlled-Release Latanoprost Insert for the Treatment of Glaucoma
PR Newswire - Mon Jun 30, 8:00AM CDT
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D®, the company's controlled-release latanoprost insert for the treatment of glaucoma.
BOLT: 21.99 (+0.01)
BioLight Announces Issuance of U.S. Patent for the Long-Term Controlled-Release Drug-Delivery Insert Platform
PR Newswire - Wed Jul 02, 8:23AM CDT
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT) (OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces the U.S. Patent and Trademark Office has issued patent number 8,765,166 covering the device that is inserted into the eye to treat an ocular condition that contains an active agent of a free acid salt form of a prostaglandin with a low elution rate profile that is contained in the long-term controlled-release insert platform. The patent will be in effect at least until May 2031. This patent covers the technology used in Eye-D®, the company's controlled-release latanoprost insert currently in a Phase 1/2a clinical study in the U.S. for the treatment of glaucoma.
BOLT: 21.99 (+0.01)
BioLight Reports Successful Interim Results from Bladder Cancer Clinical Study
PR Newswire - Tue Jul 01, 4:23PM CDT
BioLight Life Sciences Investments Ltd. (OTC: BLGTY)(TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that Micromedic Technologies (TASE: MCTC), BioLight's cancer diagnostic cluster company, achieved successful interim results in a blinded bladder cancer clinical trial with its CellDetect® technology. As a result, Micromedic will continue the trial with the goal of developing a kit for monitoring the recurrence of bladder cancer. This study is being conducted at seven medical centers and is expected to be completed in the fourth quarter of 2014.
BOLT: 21.99 (+0.01)
First Patient Enrolled in FDA Phase 1/2a Clinical Trial With BioLight's Controlled-Release Latanoprost Insert for the Treatment of Glaucoma
PR Newswire - Mon Jun 30, 8:00AM CDT
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D®, the company's controlled-release latanoprost insert for the treatment of glaucoma.
BOLT: 21.99 (+0.01)
